Analysts think KRYS stock price could increase by 36%
Apr 11, 2025, 11:25 AM
-17.81%
What does KRYS do
Krystal Biotech, based in Pittsburgh, focuses on developing genetic medicines for diseases with high unmet needs, employing 229 staff since its IPO in September 2017. Its products include VYJUVEK for DEB and others targeting cystic fibrosis and solid tumors.
12 analysts think KRYS stock price will increase by 36.30%. The current median analyst target is $219.30 compared to a current stock price of $160.90. The lowest analysts target is $196.95 and the highest analyst target is $257.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
